A Phase 2/3 interventional study of tadalafil and tadalafil in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2009-09-02.
Sponsored by Eli Lilly and Company · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one has the largest enrollment, is one of 2 that started in 2006, is the only one in phase 2/3, and was the 1st registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Assiut University
Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 45 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 11 · Phase 4 6
First in 2004; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,058 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 258 across the 26 interventional studies. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 26 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
17 studies in Prostatic Hyperplasia by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 17 finished, 16 (94%) have results posted.
Among the 17 studies in Prostatic Hyperplasia by Eli Lilly and Company, this one has the largest enrollment, is one of 2 that started in 2006, is the only one in phase 2/3, and was the 1st registered.
Eli Lilly and Company’s Prostatic Hyperplasia studies by the year they started, since 2004.
1 of the studies testing tadalafil in Prostatic Hyperplasia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07654413Beni-Suef UniversityTamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 17 in Prostatic Hyperplasia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled, parallel-design, multinational, 12-week study to compare the efficacy, dose response, and safety of tadalafil once a day versus placebo in men with signs and symptoms of benign prostatic hyperplasia, including lower urinary tract symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
placebo tablet
Drug: placebo
2.5 mg tadalafil tablet
Drug: tadalafil
5 mg tadalafil tablet
Drug: tadalafil
10 mg tadalafil tablet
Drug: tadalafil
20 mg tadalafil tablet
Drug: tadalafil
2.5 mg tadalafil tablet by mouth once a day for twelve weeks.
Also known as: LY450190, Cialis, IC351
5 mg tadalafil tablet by mouth once a day for twelve weeks.
Also known as: LY450190, Cialis, IC351
10 mg tadalafil tablet by mouth once a day for twelve weeks.
Also known as: LY450190, Cialis, IC351
20 mg tadalafil tablet by mouth once a day for twelve weeks.
Also known as: LY450190, Cialis, IC351
Placebo tablet taken by mouth one a day for twelve weeks
Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS): Primary Analysis
Assesses the severity of BPH-LUTS and the response to therapy. The total score was derived by summing the scores of the responses to the 7 component questions. Scores range from 0 to 35; 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic.
Time frame: Baseline and 12 weeks
Change From Baseline to Week 12 in International Prostate Symptom Score (IPSS): Supportive Analysis
Assesses the severity of BPH-LUTS and the response to therapy. The total score was derived by summing the scores of the responses to the 7 component questions. Scores range from 0 to 35; 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic.
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) (Irritative) Subscore
Measures irritative symptoms over the past 4 weeks of the IPSS. IPSS irritative subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 1 (few irritative symptoms) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.
Time frame: baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore
Measures obstructive symptoms over the past 4 weeks of the IPSS. IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 1 (few obstructive symptoms) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.
Time frame: 12 weeks
Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Question 7 (Nocturia)
Measures nocturia (the need to get up at night to urinate) over the past 4 weeks. Scores range from 1 (few episodes of nocturia) to 5 (frequent episodes of nocturia).
Time frame: baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index
Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).
Time frame: baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in Benign Prostatic Hyperplasia Impact Index (BII)
Measures the impact that symptoms of BPH has on the patients well being. This questionnaire has 4 questions assessing the level of urinary discomfort and it's impact on the patients. Three questions range from 0 (no impact) to 4 (high impact); one question ranges from 0 (low impact) to 4 (high impact). The BII score ranges from 0 to 16.
Time frame: baseline and 12 weeks
Number of Participants Who Answer "Yes" to the Lower Urinary Tract Symptoms (LUTS) Global Assessment Question (LUTS-GAQ)
LUTS-GAQ Question asks the participant if the treatment they have been on has improved their uninary symptoms.
Time frame: 12 weeks
Change From Baseline to 12 Week Endpoint in Peak Urinary Flow
Measures the maximum flow rate of urine (measured in mL/s). This is a continuous parameter with positive numeric values.
Time frame: baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) EF Domain
Measures erectile function over the past 4 weeks on Questions 1-5 and 15 (6 questions) of the International Index of Erecile Function (IIEF) questionnaire. Scores range from 0 (low/no erectile function) to 5 (high erectile function), thus the 6 questions of the IIEF-EF domain range from 0 to 30.
Time frame: baseline and 12 weeks
| Milestone | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil |
|---|---|---|---|---|---|
| Started | 212 | 209 | 212 | 216 | 209 |
| Received double-blind study drug | 211 | 208 | 212 | 216 | 209 |
| Completed | 185 | 182 | 182 | 175 | 162 |
| Not completed | 27 | 27 | 30 | 41 | 47 |
| Withdrew: Adverse event | 5 | 4 | 12 | 11 | 14 |
| Withdrew: Entry criteria not met | 2 | 6 | 7 | 8 | 4 |
| Withdrew: Lack of efficacy | 1 | 1 | 2 | 1 | 2 |
| Withdrew: Lost to follow-up | 5 | 3 | 0 | 4 | 6 |
| Withdrew: Physician decision | 0 | 1 | 1 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 6 | 4 |
| Withdrew: Sponsor decision | 3 | 4 | 0 | 5 | 0 |
| Withdrew: Withdrawal by subject | 9 | 7 | 7 | 6 | 16 |
| Withdrew: Didn't receive double-blind study drug | 1 | 1 | 0 | 0 | 0 |
Assesses the severity of BPH-LUTS and the response to therapy. The total score was derived by summing the scores of the responses to the 7 component questions. Scores range from 0 to 35; 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic.
| units on a scale | Placebo | 5 mg Tadalafil |
|---|---|---|
| Baseline | 17.08 ± 6.36 | 17.30 ± 5.97 |
| Change from Baseline | -2.25 ± 6.17 | -4.92 ± 5.67 |
Measures irritative symptoms over the past 4 weeks of the IPSS. IPSS irritative subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 1 (few irritative symptoms) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.
| units on a scale | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil |
|---|---|---|---|---|---|
| Baseline | 7.58 ± 3.09 | 7.78 ± 2.86 | 7.65 ± 2.84 | 7.88 ± 2.67 | 7.53 ± 3.07 |
| Change from Baseline | -0.99 ± 2.92 | -1.62 ± 2.83 | -1.91 ± 2.64 | -2.04 ± 2.75 | -2.05 ± 2.86 |
Measures obstructive symptoms over the past 4 weeks of the IPSS. IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 1 (few obstructive symptoms) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.
| units on a scale | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil |
|---|---|---|---|---|---|
| Baseline | 9.51 ± 4.21 | 9.71 ± 4.16 | 9.65 ± 4.10 | 9.88 ± 3.87 | 9.57 ± 4.45 |
| Change from Baseline | -1.27 ± 4.00 | -2.31 ± 3.84 | -3.00 ± 3.87 | -3.29 ± 4.04 | -3.17 ± 4.02 |
Measures nocturia (the need to get up at night to urinate) over the past 4 weeks. Scores range from 1 (few episodes of nocturia) to 5 (frequent episodes of nocturia).
| units on a scale | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil |
|---|---|---|---|---|---|
| Baseline | 2.36 ± 1.10 | 2.37 ± 1.31 | 2.36 ± 1.91 | 2.36 ± 1.15 | 2.20 ± 1.23 |
| Change from Baseline | -0.36 ± 1.09 | -0.43 ± 1.33 | -0.49 ± 1.17 | -0.43 ± 1.28 | -0.54 ± 1.17 |
Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).
| units on a scale | Placebo | 2.5 mg Tadalafil | 5.0 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil |
|---|---|---|---|---|---|
| Baseline | 3.57 ± 1.19 | 3.69 ± 1.19 | 3.54 ± 1.30 | 3.55 ± 1.23 | 3.59 ± 1.28 |
| Change from Baseline | -0.56 ± 1.20 | -0.86 ± 1.13 | -0.92 ± 1.30 | -0.98 ± 1.46 | -0.97 ± 1.27 |
Measures the impact that symptoms of BPH has on the patients well being. This questionnaire has 4 questions assessing the level of urinary discomfort and it's impact on the patients. Three questions range from 0 (no impact) to 4 (high impact); one question ranges from 0 (low impact) to 4 (high impact). The BII score ranges from 0 to 16.
| units on a scale | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil |
|---|---|---|---|---|---|
| Baseline | 4.94 ± 2.95 | 4.73 ± 2.95 | 4.66 ± 2.98 | 4.86 ± 2.98 | 4.75 ± 2.79 |
| Change from Baseline | -0.79 ± 2.52 | -0.83 ± 2.66 | -1.25 ± 2.75 | -1.31 ± 2.79 | -1.34 ± 2.41 |
LUTS-GAQ Question asks the participant if the treatment they have been on has improved their uninary symptoms.
| participants | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil |
|---|---|---|---|---|---|
| Number of Participants Who Answer "Yes" to the Lower Urinary Tract Symptoms (LUTS) Global Assessment Question (LUTS-GAQ) | 109 | 120 | 139 | 146 | 138 |
Measures the maximum flow rate of urine (measured in mL/s). This is a continuous parameter with positive numeric values.
| milliliter per second | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil |
|---|---|---|---|---|---|
| Baseline | 10.31 ± 4.85 | 9.97 ± 4.09 | 10.37 ± 3.86 | 9.93 ± 3.77 | 9.82 ± 3.97 |
| Change from Baseline | 1.23 ± 5.01 | 1.50 ± 4.56 | 1.61 ± 3.95 | 1.69 ± 4.46 | 2.15 ± 4.69 |
Measures erectile function over the past 4 weeks on Questions 1-5 and 15 (6 questions) of the International Index of Erecile Function (IIEF) questionnaire. Scores range from 0 (low/no erectile function) to 5 (high erectile function), thus the 6 questions of the IIEF-EF domain range from 0 to 30.
| units on a scale | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil |
|---|---|---|---|---|---|
| Baseline | 17.26 ± 7.95 | 17.42 ± 8.30 | 15.29 ± 8.13 | 17.22 ± 8.43 | 16.28 ± 8.05 |
| Change from Baseline | 0.78 ± 6.32 | 3.97 ± 7.30 | 6.56 ± 9.43 | 6.64 ± 8.29 | 7.44 ± 8.42 |
Assesses the severity of BPH-LUTS and the response to therapy. The total score was derived by summing the scores of the responses to the 7 component questions. Scores range from 0 to 35; 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic.
| units on a scale | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil |
|---|---|---|---|---|---|
| Change From Baseline to Week 12 in International Prostate Symptom Score (IPSS): Supportive Analysis | -2.23 ± 0.49 | -3.81 ± 0.50 | -4.83 ± 0.49 | -5.13 ± 0.48 | -5.17 ± 0.50 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | — | — |
| 2.5 mg Tadalafil | — | — | — |
| 5 mg Tadalafil | — | — | — |
| 10 mg Tadalafil | — | — | — |
| 20 mg Tadalafil | — | — | — |
| Event | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil |
|---|---|---|---|---|---|
| Atrial tachycardiaCardiac disorders | 0/212 | 1/209 | 0/212 | 0/216 | 0/209 |
| Myocardial infarctionCardiac disorders | 0/212 | 1/209 | 0/212 | 0/216 | 0/209 |
| ArthritisMusculoskeletal and connective tissue disorders | 1/212 | 0/209 | 0/212 | 1/216 | 1/209 |
| Back painMusculoskeletal and connective tissue disorders | 0/212 | 0/209 | 0/212 | 0/216 | 1/209 |
| Bladder neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/212 | 1/209 | 0/212 | 0/216 | 0/209 |
| Cerebrovascular accidentNervous system disorders | 1/212 | 0/209 | 0/212 | 0/216 | 1/209 |
| NephrolithiasisRenal and urinary disorders | 0/212 | 1/209 | 0/212 | 0/216 | 0/209 |
| Renal failure acuteRenal and urinary disorders | 0/212 | 1/209 | 0/212 | 0/216 | 0/209 |
| Ureteric ruptureRenal and urinary disorders | 0/212 | 1/209 | 0/212 | 0/216 | 0/209 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/212 | 0/209 | 0/212 | 0/216 | 1/209 |
| Event | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil |
|---|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 1/212 | 3/209 | 2/212 | 10/216 | 11/209 |
| HeadacheNervous system disorders | 6/212 | 5/209 | 6/212 | 11/216 | 7/209 |
| DyspepsiaGastrointestinal disorders | 0/212 | 2/209 | 10/212 | 6/216 | 10/209 |
| NasopharyngitisInfections and infestations | 2/212 | 7/209 | 4/212 | 2/216 | 5/209 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/212 | 3/209 | 3/212 | 6/216 | 6/209 |
| DiarrhoeaGastrointestinal disorders | 3/212 | 2/209 | 6/212 | 1/216 | 5/209 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/212 | 2/209 | 2/212 | 6/216 | 3/209 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/212 | 2/209 | 0/212 | 2/216 | 5/209 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/212 | 3/209 | 5/212 | 2/216 | 3/209 |
| BronchitisInfections and infestations | 1/212 | 3/209 | 1/212 | 5/216 | 0/209 |
| Age Continuous(years) | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil | Total |
|---|---|---|---|---|---|---|
| Mean | 61.75 ± 7.69 | 62.03 ± 8.42 | 61.95 ± 8.17 | 62.22 ± 7.20 | 62.55 ± 8.09 | 62.10 ± 7.91 |
| Sex: Female, Male(Participants) | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 211 | 208 | 212 | 216 | 209 | 1056 |
| Region of Enrollment(participants) | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil | Total |
|---|---|---|---|---|---|---|
| Australia | 4 | 5 | 5 | 6 | 4 | 24 |
| Canada | 12 | 5 | 9 | 13 | 6 | 45 |
| France | 13 | 12 | 9 | 15 | 11 | 60 |
| Germany | 29 | 35 | 39 | 28 | 33 | 164 |
| Greece | 8 | 9 | 12 | 11 | 10 | 50 |
| Italy | 15 | 10 | 5 | 9 | 9 | 48 |
| Mexico | 19 | 16 | 17 | 19 | 19 | 90 |
| Spain | 3 | 3 | 2 | 5 | 4 | 17 |
| Sweden | 4 | 2 | 5 | 4 | 5 | 20 |
| United States | 105 | 112 | 109 | 106 | 108 | 540 |
| Baseline (Visit 3) Lower Urinary Tract Symptoms (LUTS) Severity(participants) | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil | Total |
|---|---|---|---|---|---|---|
| Moderate (<20 units on a scale: IPSS) | 137 | 139 | 141 | 143 | 141 | 701 |
| Severe (>=20 units on a scale: IPSS) | 74 | 69 | 71 | 72 | 68 | 354 |
| Unknown | 0 | 0 | 0 | 1 | 0 | 1 |
| Duration of Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)(participants) | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil | Total |
|---|---|---|---|---|---|---|
| < 6 months | 0 | 0 | 0 | 1 | 0 | 1 |
| 6 months to 1 year | 44 | 27 | 37 | 27 | 39 | 174 |
| 1 year to 3 years | 62 | 64 | 63 | 81 | 70 | 340 |
| > 3 years | 105 | 117 | 112 | 107 | 100 | 541 |
| Erectile Dysfunction(participants) | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil | Total |
|---|---|---|---|---|---|---|
| Yes | 142 | 135 | 144 | 150 | 145 | 716 |
| No | 67 | 71 | 68 | 64 | 61 | 331 |
| Unknown | 1 | 2 | 0 | 2 | 3 | 8 |
| Not Collected | 1 | 0 | 0 | 0 | 0 | 1 |
| Previous Therapy for Benign Prostatic Hyperplasia (BPH)(participants) | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil | Total |
|---|---|---|---|---|---|---|
| No | 153 | 139 | 158 | 160 | 152 | 762 |
| Yes | 58 | 69 | 54 | 56 | 57 | 294 |
| Race/Ethnicity(participants) | Placebo | 2.5 mg Tadalafil | 5 mg Tadalafil | 10 mg Tadalafil | 20 mg Tadalafil | Total |
|---|---|---|---|---|---|---|
| African | 3 | 3 | 7 | 5 | 5 | 23 |
| Caucasian | 179 | 184 | 179 | 186 | 176 | 904 |
| East Asian | 0 | 1 | 1 | 0 | 0 | 2 |
| Hispanic | 29 | 20 | 25 | 24 | 25 | 123 |
| West Asian | 0 | 0 | 0 | 1 | 3 | 4 |
3 further baseline measures are reported on the registry.
The record gives a start of Aug 2006, a primary completion of Oct 2007 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil